<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003336</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU5Y97</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-5Y97</secondary_id>
    <secondary_id>NCI-G98-1431</secondary_id>
    <secondary_id>CASE-5Y97</secondary_id>
    <nct_id>NCT00003336</nct_id>
  </id_info>
  <brief_title>Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions</brief_title>
  <official_title>A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of&#xD;
      chemotherapy or radiation therapy and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well umbilical cord blood transplantation works&#xD;
      in treating patients with severe aplastic anemia, malignant thymoma, or myelodysplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the rates of durable engraftment in patients with severe aplastic anemia,&#xD;
           myelodysplastic syndrome, inborn errors of metabolism, or inherited hematopoietic&#xD;
           disorders, refractory to medical management, who are undergoing high-dose&#xD;
           chemoradiotherapy followed by unrelated cord blood (UCB) transplantation.&#xD;
&#xD;
        -  Evaluate the rate and quality of immunologic reconstitution in this patient population.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to weight (under 45 kg vs over 45 kg).&#xD;
&#xD;
      Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen&#xD;
      beginning 6-9 days before the umbilical cord blood transplant (UCBT). The regimen varies&#xD;
      according to the underlying cause of the anemia, but could include busulfan, cyclophosphamide&#xD;
      or melphalan, anti-thymocyte globulin or methylprednisolone, and/or radiation therapy. One&#xD;
      day after the conditioning regimen is completed, patients receive the UCBT.&#xD;
&#xD;
      Patients are followed weekly for 3 months, at 6 months, then every 6 months for 2.5 years,&#xD;
      then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 4-90 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival by disease assessment</measure>
    <time_frame>at 100 days and at 6, 9, 12, 18, and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC) at time of myeloid recovery.</measure>
    <time_frame>100 days and at 6, 9, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>One day after the conditioning regimen is completed, patients receive the UCBT.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of severe aplastic anemia based on bone marrow&#xD;
             cellularity of less than 20%&#xD;
&#xD;
          -  Must meet at least two of the following criteria:&#xD;
&#xD;
               -  Granulocyte count less than 500/mm^3&#xD;
&#xD;
               -  Platelet count less than 20,000/mm^3&#xD;
&#xD;
               -  Reticulocyte count less than 50,000/mm^3&#xD;
&#xD;
          -  Following etiologies eligible:&#xD;
&#xD;
               -  Fanconi's anemia&#xD;
&#xD;
               -  Hypoplastic leukemia&#xD;
&#xD;
               -  Monosomy 7&#xD;
&#xD;
               -  Drug exposure (chloramphenicol, NSAIDS)&#xD;
&#xD;
               -  Viral exposure (EBV, hepatitis, parvovirus, HIV)&#xD;
&#xD;
               -  Nutritional deficiencies&#xD;
&#xD;
               -  Thymoma&#xD;
&#xD;
               -  Paroxysmal nocturnal hemoglobinuria&#xD;
&#xD;
               -  Amegakaryocytic thrombocytopenia OR&#xD;
&#xD;
          -  Histologically confirmed myelodysplastic syndrome (MDS) that is refractory to medical&#xD;
             management or with cytogenic abnormalities predictive of transformation into acute&#xD;
             leukemia, including 5q-, 7q-, monosomy 7, or trisomy 8&#xD;
&#xD;
          -  The following etiologies only are eligible:&#xD;
&#xD;
               -  Refractory anemia&#xD;
&#xD;
               -  Refractory anemia with ringed sideroblasts&#xD;
&#xD;
               -  De novo primary MDS&#xD;
&#xD;
               -  Therapy-related secondary MDS OR&#xD;
&#xD;
          -  Confirmed diagnosis of inherited hematopoietic disorder that is refractory to medical&#xD;
             management&#xD;
&#xD;
          -  Following etiologies eligible:&#xD;
&#xD;
               -  Severe combined immunodeficiency&#xD;
&#xD;
               -  Familial erythrophagocytic lymphohistiocytosis&#xD;
&#xD;
               -  Wiskott-Aldrich syndrome&#xD;
&#xD;
               -  Kostmann's syndrome (infantile histiocytosis)&#xD;
&#xD;
               -  Chronic granulomatous disease&#xD;
&#xD;
               -  Leukocytic adhesion deficiency&#xD;
&#xD;
               -  Chediak-Higashi syndrome&#xD;
&#xD;
               -  Paroxysmal nocturnal hemoglobinuria&#xD;
&#xD;
               -  Fanconi's anemia&#xD;
&#xD;
               -  Dyskeratosis congenita&#xD;
&#xD;
               -  Diamond-Blackfan anemia&#xD;
&#xD;
               -  Amegakaryocytic thrombocytopenia&#xD;
&#xD;
               -  Osteopetrosis&#xD;
&#xD;
               -  Gaucher's disease&#xD;
&#xD;
               -  Lesch-Nyhan syndrome&#xD;
&#xD;
               -  Mucopolysaccharidoses&#xD;
&#xD;
               -  Lipodoses&#xD;
&#xD;
          -  Autologous or haploidentical related peripheral blood stem cells available as backup&#xD;
&#xD;
          -  Serologically matched umbilical cord blood unit available in the New York Blood&#xD;
             Center's Placental Blood Project, or other acceptable umbilical cord blood registry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  55 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  ALT/AST no greater than 4 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Normal cardiac function by echocardiogram or radionuclide scan&#xD;
&#xD;
          -  Shortening fraction or ejection fraction at least 80% normal for age&#xD;
&#xD;
          -  Non-Fanconi patients with acquired or congenital cardiomyopathy may receive melphalan&#xD;
             as a substitute for cyclophosphamide&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FVC and FEV_1 at least 60% of predicted for age&#xD;
&#xD;
          -  DLCO at least 60% of predicted in adult patients&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active concurrent malignancy&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Must have an available serologic matched Umbilical Cord Blood Unit (UCBU) in the New&#xD;
             York Blood Center's Placental Blood Project, or other acceptable Umbilical Cord Blood&#xD;
             (UCB) registry&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent immunosuppressive medications&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary J. Laughlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-7284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001 Jun 14;344(24):1815-22. doi: 10.1056/NEJM200106143442402.</citation>
    <PMID>11407342</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mary J. Laughlin, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

